AIVITA Biomedical
18301 Von Karman Avenue
Suite 130
Irvine
California
92612
United States
Tel: 949-872-2555
Website: http://aivitabiomedical.com/
About AIVITA Biomedical
AIVITA Biomedical is a privately held company engaged in the advancement of commercial and clinical-stage programs utilizing curative and regenerative medicines. Founded in 2016 by pioneers in the stem cell industry, AIVITA Biomedical utilizes its expertise in stem cell growth and directed, high-purity differentiation to enable safe, efficient and economical manufacturing systems which support its products and therapeutic pipeline.
YEAR FOUNDED:
2016
LEADERSHIP:
CEO: Dr. Hans S. Keirstead Ph.D.
CMO: Robert O. Dillman, M.D.
CSO: Gabriel Nistor, M.D.
TECHNOLOGY:
Please click here for AIVITA's technology.
PRODUCTS:
Please click here for AIVITA's products.
99 articles about AIVITA Biomedical
-
AIVITA Biomedical Publishes Study Comparing Immune Responses and Associated Survivals Induced by Dendritic and Tumor Cell Vaccines
4/23/2020
Findings confirmed that patient-specific autologous dendritic cell vaccines (DCV) induced a different immune response associated with longer survival than autologous tumor cell vaccines (TCV) – IRVINE, Calif.--( BUSINESS WIRE )-- AIVITA Biomedical, Inc., a biotechnology company specializing in innovative cell therapy applications, announced today the publication of a paper titled, “Cytokine network analysis of immune responses before and after au
-
AIVITA Biomedical Provides Update of Ongoing Phase 2 Glioblastoma Trial from Year-End Survival Analysis
4/8/2020
AIVITA Biomedical, Inc., a biotechnology company specializing in innovative cell therapy applications, announced today updated survival data from a year-end analysis of its ongoing Phase 2 clinical trial of AV-GBM-1 in patients with newly diagnosed glioblastoma (GBM). In the analysis, the overall survival rate at both 12 and 1
-
AIVITA Biomedical Raises $12.5 Million in Series B-2 Financing Round and Announces New Board of Directors Appointee
2/25/2020
AIVITA Biomedical, Inc., a biotechnology company (the "Company") specializing in innovative stem cell applications, announced today the first closing of its $25 million Series B-2 preferred stock investment round.
-
AIVITA Biomedical Completes Patient Recruitment in Phase 2 GBM Trial
2/4/2020
Trial Investigating Personalized Cancer Immunotherapy Achieves 94% Manufacturing Success Rate [04-February-2020] IRVINE, Calif. , Feb. 4, 2020 /PRNewswire/ -- AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, announced today that it has reached its patient enrollment target in the Company's Phase 2 clinical trial for gliobla
-
AIVITA Biomedical to Present at Biotech Showcase 2020
1/14/2020
Dr. Hans S. Keirstead, AIVITA's Chairman and CEO, will present at the following time and location:
-
ROOT OF SKIN™ Skincare Products Sell Out on Every QVC Japan Show in 2019
1/8/2020
AIVITA Biomedical, Inc. announced that the Company's ROOT of SKIN™ line of rejuvenating skincare products sold out in its 11th and 12th appearances in December 2019 on the Japanese home shopping channel QVC Japan.
-
AIVITA Biomedical Announces New Positive Phase 2 Glioblastoma Data at SITC Annual Meeting Podium Presentation
11/12/2019
AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, announced that data from its ongoing Phase 2 clinical trial in GBM was presented at the Society for Immunotherapy of Cancer Annual Meeting by Principal Investigator Dr. Daniela Bota.
-
Brain Cancer Patient Survival, Immune and Tumor Data from AIVITA Biomedical's Phase 2 Clinical Trial to be Presented at SITC Annual Meeting
11/8/2019
AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, today announced that new data from its ongoing Phase 2 clinical trial in glioblastoma multiforme will be presented at the Society for Immunotherapy of Cancer Annual Meeting by Lead Principal Investigator Dr. Daniela Bota.
-
AIVITA Biomedical to Present at Upcoming Regenerative Medicine, Oncology and Investor Conferences in November
11/1/2019
AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, today announced that it will be presenting at the following regenerative medicine and investor conferences in November:
-
AIVITA Biomedical Announces Publication Detailing Immune Mechanisms Leading to Complete Remission of Measurable Metastatic Melanoma in Patient Treated with AIVITA Immunotherapy
10/30/2019
AIVITA Biomedical, Inc., a biotechnology company specializing in innovative stem cell applications, announced the publication of an article titled "Genomic, Proteomic, and Immunologic Associations with a Durable Complete Remission of Measurable Metastatic Melanoma Induced by a Patient-Specific Dendritic Cell Vaccine" in the journal Human Vaccines and Immunotherapeutics.
-
Brain Cancer Patients Display Appropriate Immune Responses and Decreasing Tumor Biomarkers in AIVITA Biomedical's Phase 2 Clinical Trial
10/24/2019
This immunological response is accompanied by decreased tumor load in approximately 81% of those same patients, equivalent to 65% of the total number of treated patients.
-
AIVITA Biomedical Announces Publication Comparing Clinical Outcomes in Patients Treated with AIVITA's Immunotherapy and Other Immunotherapies
10/17/2019
AIVITA Biomedical, Inc., a biotechnology company specializing in innovative stem cell applications, announced the publication of an article titled "Survival Comparison between Melanoma Patients Treated with Patient-Specific Dendritic Cell Vaccines and Other Immunotherapies Based on Extent of Disease at the Time of Treatment" in the journal Biomedicines.
-
ROOT OF SKIN™ Skincare Products Sell Out in Tenth Consecutive Appearance on QVC Japan
10/15/2019
AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, announced that the Company's ROOT of SKIN™ line of rejuvenating skincare products sold out in its tenth appearance on the Japanese home shopping channel QVC Japan.
-
AIVITA Biomedical Announces Publication Concerning a Predictive Biomarker for Melanoma Patients Treated with the Company's Platform Immunotherapy
10/2/2019
AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, today announced the publication of an article titled "Preliminary observations on soluble programmed death-1 protein as a prognostic and predictive biomarker in patients with metastatic melanoma treated with patient-specific autologous vaccines" in the oncology journal Oncotarget.
-
AIVITA CEO Dr. Hans Keirstead Honored as One of Canada's 'Seven Wonderers' at Beakerhead Festival
10/1/2019
The "Seven Wonderers" event is part of a five-day festival featuring scientists, artists, engineers, designers, inventors and performers in an all-inclusive event showcasing creativity, ingenuity, technology and art.
-
AIVITA Biomedical to Present at Meeting on the Mesa and Other Investor, Oncology and Regenerative Medicine Conferences in October
10/1/2019
AIVITA Biomedical, Inc. announced that it will be presenting at the following investor, oncology and regenerative medicine conferences in October:
-
AIVITA Biomedical Launches Professional ROOT of SKIN™ MD Skincare Line in Japan
9/10/2019
AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, announced today the launch of the Company's professional ROOT of SKIN™ MD brand of rejuvenating skincare products in Japan
-
ROOT OF SKIN™ Skincare Line Sells out in Ninth Consecutive Appearance on QVC Japan
9/9/2019
AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, announced today that the Company's ROOT of SKIN™ line of rejuvenating skincare products sold out in its ninth appearance on the Japanese home shopping channel QVC Japan
-
Brain Cancer Patients Display Decreasing Tumor Biomarkers After Treatment with Novel Immunotherapy in AIVITA Biomedical's Phase 2 Clinical Trial
8/14/2019
AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, announced updated clinical data from its ongoing glioblastoma Phase 2 clinical trial, investigating AIVITA's platform immunotherapy targeting tumor-initiating cells.
-
AIVITA Biomedical Receives Import Approval to Distribute its Professional ROOT of SKIN™ MD Skincare Line in Japan
8/1/2019
AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, announced today that the Company has been granted a government regulatory agency import approval to begin shipping its physician-dispensed ROOT of SKIN™ MD skincare product line to Japan, adding to its prior approval to import the consumer ROOT of SKIN™ line to Japan